MELBOURNE, Australia & MENLO PARK, Calif.--(BUSINESS WIRE)--ChemGenex Pharmaceuticals (ASX:CXS - News)(NASDAQ:CXSP - News) has announced interim results from its ongoing phase 2/3 trial of omacetaxine mepesuccinate (formerly known as Ceflatonin®) in chronic myeloid leukemia (CML) patients with the T315I mutation. The data continue to show an increase in the number of patients responding with increasing duration of response in chronic and accelerated phase patients.
